ArticleAnnals of gastroenterological surgery2026
Mature Tertiary Lymphoid Structures Indicate Good Chemotherapy Response and Prognosis in Advanced Colorectal Cancer.
Article in Annals of gastroenterological surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.Cancer discovery · 2026Article
- CD86-Positive Mature Tertiary Lymphoid Structures Are Associated With CD8Annals of gastroenterological surgery · 2026Article
- A simple MRI/PET-derived index predicts relapse-free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Article
- Mechanistic roles and clinical applications of tertiary lymphoid structures in colorectal cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2026Review
- Non-immune regulation of tertiary lymphoid structures in cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tertiary lymphoid structures (TLS), clusters of immune cells including B and T cells, are involved in anti-tumor immunity and correlate with a favorable prognosis in several malignancies, but their association with systemic chemotherapy is unknown. We investigated the role of TLS as a biomarker for predicting chemotherapy efficacy in advanced colorectal cancer (CRC). Methods: We analyzed 78 CRC cases with metastatic or recurrent lesions, in which untreated resected primary tumors were available before chemotherapy. TLS maturity, defined by the presence of CD23 Results: Mature TLS-negative groups had poorer chemotherapy sensitivity, progression-free survival, and overall survival. Multivariate analysis confirmed TLS maturity as an independent predictor of both therapeutic response and survival outcomes in this cohort. Mature TLS was associated with higher CD3 Conclusion: Mature TLS may contribute to favorable chemotherapeutic efficacy through immune activity. TLS maturity in primary tumors may represent a novel biomarker for predicting systemic chemotherapy response and immune status across primary and metastatic sites in advanced CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.